Statement from Ralph G. Neas, President and CEO of the Generic Pharmaceutical Association on the Mutual v. Bartlett Supreme Court Ruling

Published Online: Monday, June 24, 2013
PRESS RELEASE

WASHINGTON, DC (June 24, 2013) — “Today’s Supreme Court ruling on the Mutual v. Bartlett case upholds a key principle: decisions about the safety and efficacy of prescription drugs should rest with scientific experts at the Food and Drug Administration (FDA).

When it comes to decisions on safety and approval of prescription medicine, the FDA is best equipped to make judgments that affect patients. The experts at FDA alone have the scientific knowledge, regulatory experience, and complete data to make these decisions.

The FDA’s job is to evaluate drugs on the science and make decisions that balance safety and risk with the need for access to life-saving medicines. Millions of patients rely on drugs like sulindac, which has been on the market for more than 30 years. It was prescribed and dispensed more than 300 million times between 2007-2012 with a typical safety profile. Decisions with this much at stake belong in the hands of the scientific, public health and regulatory experts at the FDA.

Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$